Advanced Therapies Commercialization

 

Advanced Therapies - Commercialization, Wednesday 29 April 2020

last published: 31/Jan/20 21:55

 

Advanced Therapies - Commercialization, Thursday 30 April 2020

Ellen Coleman
08:25

Chairperson’s opening remarks

Ellen Coleman, President And Chief Executive Officer, VOZ Advisors
Emil Kakkis
08:30

Keynote Address: The future of rare diseases: developing and accessing the next generation of therapies

Emil Kakkis, Chief Executive Officer, Ultragenyx Pharmaceutical
Mark Rothera
08:55

Sponsored Keynote Address: Gene therapy: the future is now

Mark Rothera, President And Chief Executive Officer, Orchard Therapeutics
Christopher Austin
09:20

Keynote Panel: The moment is now for rare diseases, but how do we advance scientific innovation, data sharing, and the commercial landscape to expedite treatments for the remaining 6,000+ diseases

Moderator: Christopher Austin, Director, National Center For Advancing Translational Sciences (Ncats), National Institutes of Health (NIH)
Peter Marks, Director, Center For Biologics Evaluation And Research (Cber), U.S. Food and Drug Administration
Janet Woodcock, Director Of Drug Evaluation And Research Center, Food and Drug Administration (FDA)
10:30

10:30 SPEED NETWORKING FOLLOWED BY MORNING NETWORKING BREAK

Delivery to patients

Advanced Therapies - Commercialization
11:30

Commercializing advanced therapies for a rare population – the bluebird bio experience

Parag Meswani
Advanced Therapies - Commercialization
11:50

Integrating a patient-first mindset in the development and commercialization of gene therapies

Parag Meswani, Senior Vice President Of Commercial Strategy And Operations, Axovant Sciences
Chuck Bucklar
Advanced Therapies - Commercialization
12:10

Getting new advanced therapy products to patients through stable hospital system – considerations for site operations and reimbursement

Chuck Bucklar, Group Vice President, Commercial Operations North America, BioMarin Pharmaceutical Inc.
Gavin Jones
Advanced Therapies - Commercialization
12:30

Communication considerations when commercializing advanced therapies

Sponsored by OPEN Health
Gavin Jones, Director Of Rare Disease, OPEN Health
Pamela Gavin
13:00

Lunch Keynote Panel: Examining industry data strategies and use of AI to advance rare disease patient identification, R&D, and commercialization

Pamela Gavin, Chief Strategy Officer, National Organization for Rare Disorders (NORD)
Sean Khozin, Global Head Of Data Strategy, Johnson & Johnson
Thomas Abbott, Head, Real World Data And Evidence, Astellas Pharma
Jan Nielsen
14:20

ROUNDTABLE 10: Patient and provider experiences - A tailored tech + talent approach to enhance the journey

Jan Nielsen, Division President, Patient Solutions, AssistRx Patient Solutions
Rachel Sher
14:20

ROUNDTABLE 11: Orphan Drug Act-assessing the impact since 1983 and looking forward

Rachel Sher, Vice President Policy And Regulatory Affairs, NORD
Alexander Natz
14:20

ROUNDTABLE 12: Real World Evidence – examining recent cases of real world evidence for approvals and reimbursement in Europe

Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Kristin Anthony
14:20

ROUNDTABLE 14: Rare Cancer – advancing best practices and partnerships for rare cancer diagnosis and drug

Kristin Anthony, President, Pten Hamartoma Tumor Syndrome Foundation
Abby Sandler, Executive Director, Mypart, Center For Cancer Research,, National Institutes of Health
Andrea Furia-Helms
14:20

ROUNDTABLE 15: Title to be announced

Andrea Furia-Helms, Director, Patient Affairs Staff, U.S. Food and Drug Administration (FDA)
Sara Nochur
14:20

ROUNDTABLE 16: Diversity & inclusion - The importance of D&I in a global company - exploring its impact on employee morale, engagement and retention of workforce, and also the need for D&I in clinical

Sara Nochur, Senior Vice President Regulatory Affairs, Alnylam Pharaceuticals
Jennifer Helfer
14:20

ROUNDTABLE 17: Internal Patient Perspective – blocking and tackling actionable implementation of patient voice throughout company functions

Jennifer Helfer, Director, Global Patient Advocacy Lead, bluebird bio
Debbie Drell
14:20

ROUNDTABLE 18: Splinter Groups - How to advance your organization, unify communities and focus on your mission while navigating challenges with personalities, emotions and leadership differences among

Debbie Drell, Director Of Membership, National Organization for Rare Disorders (NORD)
Nataliya Shandarovska
14:20

ROUNDTABLE 19: Diagnostic access programs – advancing access to rare disease diagnosis in emerging markets

Nataliya Shandarovska, Patient Advocate, National Alliance for Rare Diseases Support - Malta
Vladimir Tomov, Chairman, National Alliance of People with Rare Diseases - Bulgaria
Scott Schliebner
14:20

ROUNDTABLE 1: Reducing study burden – approaches for assessing and reducing the burden of clinical trial participation for patients

Scott Schliebner, Vice President, Scientific Affairs, Rare Diseases, PRA Health Sciences
14:20

ROUNDTABLE 23: Gene therapy education – best practices for educate patient populations on the science and implications of gene therapy

Chelsea Catsburg
14:20

ROUNDTABLE 2: Synthetic control arms - using RWE to streamline the regulatory process

Chelsea Catsburg, Engagement Manager, BluePrint Orphan
Scott Gray
14:20

ROUNDTABLE 3: The patient journey - improving clinical trial performance and delivering better study outcomes through a personalized approach to the patient experience

Scott Gray, Chief Executive Officer, Clincierge
Anne Cropp
14:20

ROUNDTABLE 4: Early Access – effective measures for successful EAPs

Anne Cropp, Chief Scientific Officer, Early Access Care
Meagan Spychala
14:20

ROUNDTABLE 5: Patient-Focused Drug Development – how to get started

Meagan Spychala, Assistant Vice President Of Patient Engagement And Program Strategy, Rho, Inc
Amanda Finlayson
14:20

ROUNDTABLE 6: Balancing the Patient Experience & ROI – understanding when to incorporate patient accommodations into study programs and balancing short and long term financial goals

Amanda Finlayson, Therapeutic Strategy Lead, ClinEdge
Michelle Berg
14:20

ROUNDTABLE 7: Gene therapy CMC – early pDNA considerations for late stage success

Michelle Berg, President, Gmp Nucleic Acids, Aldevron
David Lapidus
14:20

ROUNDTABLE 8: Forecasting & epidemiology - rare-disease epidemiology methods and resources to support commercial forecasts

David Lapidus, President, Lapidus Data
Becky Thompson
14:20

ROUNDTABLE 9: Access Programs - discussion on the value of rare and orphan access programs, next generation registries and post marketing surveillance for products

Becky Thompson, Director Integrated Solutions, PAREXEL

ROUNDTABLE SESSIONS (1-hour roundtable sessions split between 2 rounds of 30min) – Sign up for two roundtables by registration

3:20 END OF ROUNDTABLES

Hospital Collaboration

Advanced Therapies - Commercialization
15:25

Setting up international centers of excellence for advanced therapies

Speaker to be announced
Advanced Therapies - Commercialization
15:45

How best to work with hospital partners to operationalize delivery of cell and gene therapies to rare disease patients

Speaker to be announced.
Cynthia Tifft
Advanced Therapies - Commercialization
16:05

Operational consideration for getting new advanced therapy products in stable system – hospital perspective

Cynthia Tifft, Deputy Clinical Director, Office Of The Clinical Director, National Human Genome Research, National Human Genome Research Institute
Advanced Therapies - Commercialization
16:25

GOLD SPONSOR SESSION

If you are interested in sponsoring this session, contact André Singer now at +1 646 619 1797 orandre.singer@terrapinn.com
16:45

4:45 AFTERNOON NETWORKING BREAK

Nick Page
17:25

Keynote Address: KYMRIAH case study: what it takes to bring an organization from clinical to commercial scale for vector manufacture

Nick Page, Chief Operations Officer, Oxford Biomedica
James Miskin
17:35

Keynote Panel: Enabling delivery of cell and gene therapies to patients: resolving continued manufacturing bottlenecks

Moderator: James Miskin, Chief Technical Officer, Oxford Biomedica
Ran Zheng, Chief Technology Officer, Orchard Therapeutics
Jan Thirkettle, Chief Development Officer, Freeline Therapeutics
Yong Dai, Chief Technology Officer, Prevail Therapeutics
Mayo Pujols, Vice President, Head Of Global Cell And Gene Technical Development And Manufacturing, Novartis
18:05

END OF CONFERENCE DAY 1 FOLLOWED BY NETWORKING DRINKS RECEPTION

last published: 31/Jan/20 21:55